Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
Multicentered Phase II Study Evaluating the Activity and Toxicity of Liposomal Cytarabine in the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia With Resistent or Relapsed Central Nervous System Involvement
  • Phase

    Phase 2
  • Study Type

  • Status

    Active, not recruiting
  • Intervention/Treatment

    cytarabine ...
  • Study Participants

The purpose of this study is to describe the activity and toxicity of a new formulation of cytarabine called liposomal cytarabine given into the central nervous system for the treatment of central nervous system localization of acute lymphoblastic leukemia (ALL) in children and adolescents.
Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL. This formulation of the drug can be given intrathecally (into the spinal fluid), and is released slowly over a longer period, about two weeks. This allows a longer exposure of the drug to the central nervous system, and requires fewer intrathecal injections for the patient.
Study Started
Mar 31
Primary Completion
Dec 31
Study Completion
Dec 31
Last Update
Mar 05

Drug liposomal cytarabine

given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)

Intrathecal liposomal cytarabine Experimental


Inclusion Criteria:

Age < 18 years
Diagnosis of acute lymphoblastic leukemia (ALL)
Central nervous system involvement with malignant cells present in cerebrospinal fluid
CNS involvement may be refractive to prior systemic therapy, a first recurrence after prior systemic and intrathecal therapy or a second recurrence
CNS involvement may be an isolated lesion or present with other sites of disease
ECOG performance status 0-2
Life expectancy of at least 8 weeks
Absence of severe organ dysfunction
Informed consent

Exclusion Criteria:

Eligibility for AIEOP studies of first recurrence of ALL,and receiving therapy in a center participating in the AIEOP studies
Concurrent treatment with experimental therapies
Severe neurologic toxicities from previous chemotherapy
Severe coagulopathy at time of recurrence
Intrathecal therapy within 1 week of planned study therapy
Total body or head and spine radiation within 8 weeks of enrolment
Bone marrow transplant within 8 weeks of start of study therapy.
No Results Posted